|
Press Releases and Ad-hoc-Announcements 2009
December 09, 2009
|
|
MOLOGEN applies for phase 2 clinical study for cancer drug MGN 1703
 more
|
November 10, 2009
|
|
MOLOGEN applies for clinical study with cell-based gene therapy for renal cancer
more
|
November 9, 2009
|
|
MOLOGEN continues to progress
more
|
November 4, 2009
|
|
MOLOGEN reaches primary end points in MGN1703 study
more
|
September 18, 2009
|
|
MOLOGEN reaches further objective in clinical study
more
|
August 27, 2009
|
|
MOLOGEN obtains US patent for cancer treatment with cell-based gene therapy
more
|
August 19, 2009
|
|
MOLOGEN AG welcomes product licence settlement process
- arbitration proceedings initiated
more
|
August 13, 2009
|
|
MOLOGEN AG: Press Release to the First Half-Year 2009
MOLOGEN AG Looks Ahead Optimistically
more
|
July 27, 2009
|
|
MOLOGEN AG extends clinical study to include another dosing group
more
|
June 10, 2009
|
|
MOLOGEN uplisted to the Prime Standard
more
|
May 28, 2009
|
|
MOLOGEN plans to move up to the Prime Standard
more
|
May 18, 2009
|
|
MOLOGEN AG: Positive preliminary results on clinical trial with anti-cancer drug.
more
|
May 14, 2009
|
|
MOLOGEN AG: Interim Report 1st Quarter 2009
MOLOGEN AG remains on course
more
|
March 30, 2009
|
|
MOLOGEN AG: successful 2008 fiscal year
more
|
March 30, 2009
|
|
MOLOGEN AG successfully carries out a capital increase
more
|
January 19, 2009
|
|
MOLOGEN AG:
Expanded manufacturing authorisation for MIDGE®-based active substances
more
|
January 14, 2009
|
|
MOLOGEN AG:
Successful Course of Study of Cancer Drug MGN1703
more
|
|
|
NEWSLETTER |
| To subscribe to our Newsletter please
 click here
|
|
|
PRESS
RELEASES 